Omeprazole Zentiva Lab

Omeprazole, the active ingredient in Omeprazole Zentiva Lab, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and related disorders in adults and children. GNH USA supplies Omeprazole Zentiva Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazole Zentiva Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is used to manage acid‑related gastrointestinal conditions by decreasing gastric acid secretion.

- Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve ulcer healing rates. - NSAID‑induced ulcer prophylaxis: lowers risk of ulcer formation in patients requiring long‑term NSAID therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain or discomfort: mild. - Flatulence: occasional. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Vitamin B12 deficiency: long‑term use concern. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Fracture risk: possible reduction in bone mineral density with prolonged use.

Omeprazole should be used with consideration of patient‑specific factors and monitoring requirements.

- Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Evaluate need for long‑term therapy: weigh benefits against risks of prolonged use. - Monitor electrolytes: especially magnesium and calcium during extended treatment. - Counsel on symptom monitoring: advise patients to report persistent abdominal pain or unexplained weight loss. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy. - Warfarin: potential increase in INR, heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Methotrexate: increased serum levels, risk of toxicity. - Digoxin: elevated concentrations, may require dose adjustment. - Phenytoin: altered metabolism, monitor serum levels. - Ketoconazole and other azole antifungals: reduced absorption, monitor therapeutic response.